NasdaqGS:NVAXBiotechs
Is Novavax's (NVAX) Partner-Led Shift With Sanofi Quietly Rewriting Its Risk-Reward Equation?
At the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Novavax outlined a partner-led operating model centered on its Matrix-M adjuvant platform and a major collaboration with Sanofi, alongside cost and liability reduction efforts and recent institutional support such as Singapore’s use of its JN.1 Nuvaxovid vaccine.
This shift toward partnerships and a leaner structure marks a meaningful evolution in how Novavax aims to monetize its technology while reducing execution burden...